
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing positive momentum through the growing adoption of its Auryon platform in both outpatient-based and hospital settings, which is enhancing the average selling price (ASP) of its offerings. The company is projected to improve its gross margins to 52.5% as it accelerates its manufacturing initiatives and benefits from a favorable revenue mix shift towards higher-margin Med-Tech products. Additionally, management's confidence in continued growth is supported by an expanding customer base, increasing utilization rates in existing accounts, and successful pricing strategies.
Bears say
AngioDynamics Inc faces significant financial challenges, including anticipated tariff headwinds estimated at $4 million to $6 million, which could dampen profit margins. Furthermore, management has signaled concerns regarding inventory pressures in the second half of fiscal 2026 due to rising raw material costs, potentially straining operational efficiency. Although recent capital sales suggest a possible positive trend in disposable demand, the concerning inventory and cost pressures raise doubts about the company's ability to sustain growth moving forward.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares